IP Library › Granted Patent US 12,653,801
Granted Patent B2
US 12,653,801 · App. 18/018,951 · Granted Jun 16, 2026

Digestive lipase activity inhibitor, blood triglyceride concentration increase inhibitor, and fat absorption inhibitor

Inventors: Hiroaki Iitsuka (Kyoto, JP); Sayo Morita (Kyoto, JP); Keita Koga (Kyoto, JP); Atsushi Yamatsu (Kyoto, JP); Mujo Kim (Kyoto, JP); Toma Furuta (Tokyo, JP)
Assignees: Pharma Foods International Co., Ltd.; Mitsuj DM Sugar Co., Ltd
A61K31/201A23L33/12A61P3/04A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,801
App. No.
18/018,951
Granted
Jun 16, 2026
Kind
B2
Abstract

The present invention relates to a digestive lipase activity inhibitor containing, as an active ingredient, at least one selected from the group consisting of linoleic acid and oleic acid.

Claims (13)

1 . A method for inhibiting digestive lipase activity, the method comprising administering a digestive lipase activity inhibitor to a subject in need thereof,

wherein the digestive lipase activity inhibitor comprises, as an active ingredient, linoleic acid.

2 . The method according to claim 1 , further comprising inhibiting an increase in blood triglyceride concentration by inhibiting digestive lipase activity.

3 . The method according to claim 2 , further comprising inhibiting fat absorption by inhibiting digestive lipase activity and inhibiting an increase in blood triglyceride concentration.

4 . The method according to claim 1 , wherein the digestive lipase activity inhibitor is administered in the form of a food composition or a pharmaceutical product.

5 . The method according to claim 1 , wherein the digestive lipase activity inhibitor comprises both the linoleic acid and oleic acid as active ingredients.

6 . The method according to claim 1 , wherein the digestive lipase is at least one lipase selected from the group consisting of a gastric lipase, an intestinal lipase, and a pancreatic lipase.

7 . The method according to claim 1 , wherein the digestive lipase activity inhibitor comprises the active ingredient in an amount 1% by mass or more and 5% by mass or less based on total amount of the digestive lipase activity inhibitor.

8 . The method according to claim 1 , wherein the digestive lipase activity inhibitor further comprises at least one material selected from the group consisting of amino acids, proteins, carbohydrates, fats and oils, sweeteners, minerals, vitamins, flavoring agents, excipients, and binders, lubricants, disintegrators, emulsifiers, surfactants, bases, solubilizers, and suspending agents.

9 . The method according to claim 1 , wherein the digestive lipase activity inhibitor is in shape of solid, liquid, or paste.

10 . The method according to claim 1 , wherein the subject is human.

11 . The method according to claim 1 , wherein the digestive lipase activity inhibitor is administered orally.

12 . The method according to claim 1 , wherein the digestive lipase activity inhibitor is administered in an amount 50 μg or more and 300 mg or less per dose.

Assignments (2)
MERGER Recorded Mar 16, 2026
From: MITSUI DM SUGAR CO., LTD.
To: MITSUI DM SUGAR CO., LTD.
Reel/Frame 074087/0886 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2023
From: IITSUKA, HIROAKI; MORITA, SAYO; KOGA, KEITA; YAMATSU, ATSUSHI; KIM, MUJO; FURUTA, TOMA
To: PHARMA FOODS INTERNATIONAL CO., LTD.; MITSUI DM SUGAR CO., LTD.
Reel/Frame 063139/0072 →
Priority Claims (1)
JP 2020-131574 · Aug 3, 2020 · national
Continuity (1)
Related Publication 20230277493A1 · Sep 7, 2023
References Cited (23)
CN 101579020A · 2009 [cited by applicant]
CN 103284151A · 2013 [cited by applicant]
CN 104814948A · 2015 [cited by applicant]
JP 2005289951A · 2005 [cited by applicant]
JP 2006169181A · 2006 [cited by applicant]
JP 2010209051A · 2010 [cited by applicant]
JP 2014079207A · 2014 [cited by applicant]
JP 2014172901A · 2014 [cited by applicant]
WO WO2009043879A1 · 2009 [cited by examiner]
WO 2017141879A1 · 2017 [cited by applicant]
Nakagome et al., “Search for pancreatic lipase inhibitory components in Southeast Asian plants”, Proceedings of the 2013 Annual Meeting of the Japan Society for Bioscience and Biotechnology (2013) (see partial English t… [cited by applicant]
Hongo et al., “Standard Physiology,” Igaku-Shoin Ltd., p. 698, 699, 738-741 (2005) (see partial English translation). [cited by applicant]
Tanaka et al., “New Pharmacology”, Nankodo Co Ltd., 402-403 (1997) (see partial English translation). [cited by applicant]
Marrelli et al., “Metabolite profiling and biological properties of aerial parts from [cited by applicant]
Kwasowski et al., “Effects of fatty acid chain length and saturation on gastric inhibitory polypeptide release in obese hyperglycaemic (ob/ob) mice,” Bioscience Reports, 5: 701-705 (1985). [cited by applicant]
Yamada, “3. Extra-pancreatic effects of incretin,” Journal of the Japan Diabetes Society, 52 (6): 423-425 (2009) (see partial English translation). [cited by applicant]
Kurihara et al., “A visceral fat reduction effect of enoki mushroom extract”, Pharmacometrics, 78, No. 5/6, p. 129 (2010) (see partial English translation). [cited by applicant]
International Search Report issued in corresponding International Patent Application No. PCT/JP2021/028604 dated Aug. 24, 2021. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion issued in corresponding International Patent Application No. PCT/JP2021/028604 dated Feb. 16, 2023. [cited by applicant]
Larsson et al., “Effect of phosphatidylcholine and free fatty acids on the activity of pancreatic lipase-colipase,” Biochimica et Biophysica Acta, 876: 543-550 (1986). [cited by applicant]
Wang Jibao, Li Min, Jiang Yongpei, “Clinical Practical Drug Compendium”, Shaanxi Science and Technology Press, Mar. 1993, p. 293. [cited by applicant]
Biao Haiping, Zuo Qun, “Sports Nutrition”, Beijing Sport University Press, Mar. 2007, p. 35-p. 37. [cited by applicant]
Li et al., “Free Linoleic Acid and Oleic Acid Reduce Fat Digestion and Absorption In Vivo as Potent Pancreatic Lipase Inhibitors Derived from Sesame Meal,” Molecules, 27: 4910 (2022). [cited by applicant]